Passage Bio Inc. - Rasio total nilai perusahaan marang pendapatan PASG

CNS treatment patents create a defensive barrier, which is confirmed by the current valuation of Passage Bio, Inc. (PASG) relative to revenue. Price growth is based on unique DNA delivery methods to the brain and a high capital-intensive barrier to entry. Diversification of early-stage orphan research reduces regulatory risks, while 0.00 represents the current metric value.
PASG (Passage Bio Inc.): rincian analitis lan laporan miturut indikator

This indicator compares Enterprise Value (EV) to annual revenue, allowing for an assessment of the company's market value regardless of its debt load. The EV/Sales multiple trend reflects the speculative expectations of investors, which for Passage Bio, Inc. (PASG) are critically dependent on the success of a single gene platform amid a narrow market and high clinical risks.